A generics-only prescription diktat that forms part of India’s new rules pertaining to the professional conduct of registered medical practitioners (RMPs) has doctors up in arms, with pharma in a tizzy over what that may mean for its established branded generics business.
Update – NMC regulations suspended
That National Medical Commission Registered Medical Practitioner (Professional Conduct) Regulations, 2023, has now been held in abeyance and will not be operative and effective till further gazette notification on the subject by the commission.
This follows hectic parleys and strong protests by stakeholders and a meeting with Mansukh Mandaviya, India’s Minister for Health and Family Welfare.The National Medical Commission has now adopted and made effective with immediate effect the “Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002”. Under these rules, which cover a gamut of aspects, a physician is required to, “as far as possible, prescribe drugs with generic names” and ensure that there is "rational prescription and use of drugs".
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
